GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Abeona Therapeutics Inc (FRA:PCJ) » Definitions » Cyclically Adjusted Price-to-FCF

Abeona Therapeutics (FRA:PCJ) Cyclically Adjusted Price-to-FCF : (As of Jun. 01, 2025)


View and export this data going back to 1980. Start your Free Trial

What is Abeona Therapeutics Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


Abeona Therapeutics Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Abeona Therapeutics's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Abeona Therapeutics Cyclically Adjusted Price-to-FCF Chart

Abeona Therapeutics Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Abeona Therapeutics Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Abeona Therapeutics's Cyclically Adjusted Price-to-FCF

For the Biotechnology subindustry, Abeona Therapeutics's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Abeona Therapeutics's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Abeona Therapeutics's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Abeona Therapeutics's Cyclically Adjusted Price-to-FCF falls into.


;
;

Abeona Therapeutics Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Abeona Therapeutics's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2025 is calculated as:

For example, Abeona Therapeutics's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2025 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=-0.368/134.9266*134.9266
=-0.368

Current CPI (Mar. 2025) = 134.9266.

Abeona Therapeutics Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201506 -1.625 100.684 -2.178
201509 -1.778 100.392 -2.390
201512 -2.200 99.792 -2.975
201603 -1.880 100.470 -2.525
201606 -2.201 101.688 -2.920
201609 -2.769 101.861 -3.668
201612 -2.132 101.863 -2.824
201703 -3.444 102.862 -4.518
201706 -2.758 103.349 -3.601
201709 -3.554 104.136 -4.605
201712 -2.661 104.011 -3.452
201803 -3.268 105.290 -4.188
201806 -5.629 106.317 -7.144
201809 -4.794 106.507 -6.073
201812 -12.777 105.998 -16.264
201903 -7.523 107.251 -9.464
201906 -8.798 108.070 -10.984
201909 -8.761 108.329 -10.912
201912 -3.866 108.420 -4.811
202003 -3.358 108.902 -4.160
202006 -2.402 108.767 -2.980
202009 -2.512 109.815 -3.086
202012 -0.363 109.897 -0.446
202103 -3.127 111.754 -3.775
202106 -2.479 114.631 -2.918
202109 -2.326 115.734 -2.712
202112 -7.075 117.630 -8.115
202203 -2.161 121.301 -2.404
202206 -1.468 125.017 -1.584
202209 -1.069 125.227 -1.152
202212 -0.747 125.222 -0.805
202303 -0.661 127.348 -0.700
202306 -0.528 128.729 -0.553
202309 -0.219 129.860 -0.228
202312 -0.331 129.419 -0.345
202403 -0.514 131.776 -0.526
202406 -0.243 132.554 -0.247
202409 -0.237 133.029 -0.240
202412 -0.337 133.157 -0.341
202503 -0.368 134.927 -0.368

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Abeona Therapeutics  (FRA:PCJ) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Abeona Therapeutics Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Abeona Therapeutics's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Abeona Therapeutics Business Description

Industry
Traded in Other Exchanges
Address
6555 Carnegie Avenue, 4th Floor, Cleveland, OH, USA, 44103
Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is focused on developing gene therapies and plasma-based products for life-threatening rare genetic diseases. Its clinical programs consist of pz-cel, an autologous, engineered cell therapy currently in development for recessive dystrophic epidermolysis bullosa (RDEB). The Company's development portfolio also features adeno-associated virus (AAV)-based gene therapies designed to treat unmet, medically needed ophthalmic diseases using the novel.

Abeona Therapeutics Headlines

No Headlines